NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Trial Profile

NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs ALT 803 (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; GI 4000 (Primary) ; Natural killer cell therapy (Primary) ; Omega-3-acid ethyl esters (Primary) ; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Fulvestrant; Oxaliplatin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantKwest
  • Most Recent Events

    • 26 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
    • 27 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top